Conversations with customers and partners indicate that Blackline Inc (NASDAQ: BL)'s vision and technology are aligned with end-market demand, according to Oppenheimer.
Oppenheimer’s Koji Ikeda maintains a Perform rating on BlackLine.
BlackLine recently hosted its annual InTheBlack London conference for its European customers, as well as investor meetings with CFO Mark Partin. The meetings inspired confidence in the company’s growth strategy, market positioning and expanding partner channel, Ikeda said in a Thursday note.
Customers and partners report “high satisfaction levels," suggesting that BlackLine is well-positioned, the analyst said. The company has good upsell and cross-sell potential within the installed base, as well as an expanding partner channel pipeline, he said.
Ikeda said Oppenehimer has come across a potentially large new BlackLine customer.
"Anecdotally, we came across a very large enterprise in the life sciences vertical that is looking to rip-and-replace a legacy application, stating that BlackLine's speed of innovation is attractive."
BlackLine can sustain healthy growth and cash generation while gaining market share, the analyst said.
The company's products and technology vision appear aligned with rising demand for “next-gen accounting-as-a-service technology, business optimization and digital transformations in the finance department,” he said.
Oppenheimer is maintaining a Perform rating on BlackLine since 2019 is an execution year for the company, Ikeda said.
BlackLine shares were up 1.39 percent at $48.79 at the time of publication Thursday.
Jim Cramer Weighs In On Autozone, Vivint Solar, Ship Finance International And More
36 Stocks Moving In Tuesday's Pre-Market Session
Latest Ratings for BL
|Feb 2019||Goldman Sachs||Reinstates||Buy|
|Jan 2019||Raymond James||Downgrades||Outperform||Market Perform|
View More Analyst Ratings for BL
View the Latest Analyst Ratings
See more from Benzinga
- Wells Fargo Expects FedEx Margins To Remain Under Pressure From Market Woes
- OptiNose Analysts Projects Prescription Growth In 2019, Beyond
- Raymond James: RingCentral Can Sustain 30% Growth Rate
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.